表纸
市场调查报告书
商品编码
1057946

过敏性结膜炎的全球市场:规模,预测(2022年~2027年),产业趋势,成长,COVID-19影响,企业的机会分析

Allergic Conjunctivitis Market, Size, Global Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis

出版日期: | 出版商: Renub Research | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格
  • 全貌
  • 简介
  • 目录
简介

全球过敏性结膜炎的市场规模,2021年成为了16亿2,150万美元。该市场,预计2021年~2027年之间,以0.2%的年复合成长率扩大,2027年达到16亿4,260万美元。近几年,过敏性结膜炎的频率增加,全球可见痒、充血、肿等症状,给予个人生活品质大幅影响。还有尽管有过敏性结膜炎的症状,医疗机关受诊的患者非常少,大部分的患者使用市售的药,无法补足药理学性的治疗方法,过敏性结膜炎常常没有充分进行诊断和治疗的问题。

本报告提供全球过敏性结膜炎市场相关调查,市场概要,以及各国患者数和治疗完毕患者数趋势,全球开发平台药物趋势,及加入此市场的主要企业简介等资讯。

目录

第1章 简介

第2章 调查手法

第3章 摘要整理

第4章 市场动态

  • 成长促进因素
  • 课题

第5章 全球过敏性结膜炎市场与患者分析

  • 市场
  • 患者数
  • 治疗完毕患者数

第6章 占有率分析-全球过敏性结膜炎

  • 各国市场占有率
  • 患者人口占有率
  • 治疗完毕患者人口占有率
  • 各疾病类型占有率

第7章 印度-过敏性结膜炎的分析

  • 市场
  • 患者数
  • 治疗完毕患者数

第8章 中国-过敏性结膜炎的分析

  • 市场
  • 患者数
  • 治疗完毕患者数

第9章 日本-过敏性结膜炎的分析

  • 市场
  • 患者数
  • 治疗完毕患者数

第10章 美国-过敏性结膜炎的分析

  • 市场
  • 患者数
  • 治疗完毕患者数

第11章 英国-过敏性结膜炎的分析

  • 市场
  • 患者数
  • 治疗完毕患者数

第12章 法国-过敏性结膜炎的分析

  • 市场
  • 患者数
  • 治疗完毕患者数

第13章 德国-过敏性结膜炎的分析

  • 市场
  • 患者数
  • 治疗完毕患者数

第14章 义大利-过敏性结膜炎的分析

  • 市场
  • 患者数
  • 治疗完毕患者数

第15章 西班牙-过敏性结膜炎的分析

  • 市场
  • 患者数
  • 治疗完毕患者数

第16章 疾病类型-全球过敏性结膜炎市场

  • 季节性过敏性结膜炎(SAC)及全年性过敏性结膜炎(PAC)
  • 春季粘膜炎(VKC)
  • 特异反应性性角结膜炎(AKC)
  • 巨大乳头状结膜炎(GPC)

第17章 全球过敏性结膜炎开发平台药物

  • Zerviate
  • OTX-DP
  • ADX-102
  • PRT2761
  • CVXL-0074
  • AK-002
  • Bertilimumab
  • Reproxalap
  • ST-266
  • SYL-116011

第18章 波特的五力分析

  • 概要
  • 买方议价能力
  • 卖主谈判力
  • 竞争的程度
  • 新加入业者的威胁
  • 替代品的威胁

第19章 企业的分析

  • Ocular Therapeutix Inc.
  • Portola Pharmaceuticals Inc.
  • Alcon
  • Santen Pharmaceutical Co., Ltd
  • Novartis
    • 概要
    • 最近的开发
    • 收益
目录

Allergic Conjunctivitis Market is expected to reach US$ 1,642.6 Million by 2027. Allergic conjunctivitis interchangeably is also known as Ocular allergy (OA). It is a common immunological hypersensitivity disorder affecting numerous populations. In recent years, allergic conjunctivitis has been increasing in frequency, with symptoms of itching, redness, and swelling globally that significantly impact an individual's quality of life. Besides, allergic conjunctivitis is an often under diagnosed and undertreated health problem because very few patients with allergic conjunctivitis symptoms seek medical attention, whereas most patients manage with over-the-counter medications and complementary no pharmacological remedies.

Global Allergic Conjunctivitis Market Size was US$ 1,621.5 Million in 2021

Recently, the prevalence of allergic conjunctivitis has increased due to factors like rapid urbanization and an increasing number of allergens. Moreover, increasing awareness is further expected to boost the adoption of drugs for allergic conjunctivitis conditions during the forecast period. Remarkably, considering these contributively factors, a substantial influx of generic versions of prominent medications is likely to create growth opportunities for the global allergic conjunctivitis market during the forecast period. Furthermore, increasing prescription (Rx) drugs to over-the-counter (OTC) switches are also expected to boost this market.

United States dominates Global Allergic Conjunctivitis Market, Patients Population & Treated Patients Population

As per our analysis, the United States stands out as the largest market for allergic conjunctivitis treatments due to the high prevalence of allergic conjunctivitis. Further, the allergic conjunctivitis treatment market in the United States has the most dominant patient population and is also expected to have a large population base in the forecasted period. Remarkably, leading to increased demand for improved health care facilities, the country also has the most significant treated patients' population.

Further, rapid urbanization and increased particulate pollution have augmented the incidence of allergic conjunctivitis in several countries, such as India and China. However, a few factors such as a dearth of awareness among the general public concerning eye disorders and lack of health insurance control the market in France, Germany, Italy, and Spain. According to Renub Research, Global Allergic Conjunctivitis Industry has grown with a CAGR of 0.2% from 2021-2027.

Impact of Coronavirus (COVID-19) Pandemic on Global Allergic Conjunctivitis Market

COVID-19 virus outbreak in December 2019 had spread to over 100 countries across the globe. Moreover, COVID-19 affected the economy in three significant ways; by directly affecting production and demand, devising disruptions in distribution channels, and its financial influence on firms and financial markets. Further, players operating in the worldwide allergic conjunctivitis industry faced significant challenges on various fronts due to the COVID-19 pandemic.

Nevertheless, significant challenges comprise the supply of raw materials required for drug formulations due to irregularities in transportation. Moreover, distributors also experienced irregular demand for products from the retailers due to the increased number of patients suffering from COVID-19 and other life-threatening disorders.

Allergic Conjunctivitis Associated with Medical Treatment & Upcoming Therapies Are Enhancing the Market Expansion

Our report covers numerous Disease Type variants like Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC), Vernal Keratoconjunctivitis (VKC), Atopic Keratoconjunctivitis (AKC), and Giant Papillary Conjunctivitis (GPC). Moreover, in our report, we have also covered, Allergic Conjunctivitis Pipeline Drugs like Zerviate, OTX-DP, ADX-102, PRT-2761, CVXL-0074, AK-002, Bertilimumab, Reproxalap, ST-266, SYL-116011. The increase in awareness of allergic conjunctivitis associated with medical treatment & upcoming therapies is enhancing the market expansion. Moreover, numerous pharmaceutical companies are trying to develop many new treatment possibilities for allergic conjunctivitis.

Key Market Players

Major players performing in the global allergic conjunctivitis market are Ocular Therapeutix Inc., Portola Pharmaceuticals Inc., Alcon, Santen Pharmaceutical Co., Ltd., and Novartis. Key players operating in the market are tremendously focusing on developing treatments for allergic conjunctivitis. This is anticipated to drive the global allergic conjunctivitis market growth during the forecast period.

Further, the market players are considerably contributing to market growth by adopting various strategies, including new product launches, mergers and acquisitions, collaborations with the government, and technological advancements to stay competitive in the market.

Renub Research report titled "Global Allergic Conjunctivitis Market, Patients, Treated Patients By Countries (India, China, Japan, United States, United Kingdom, France, Germany, Italy, Spain), Disease Type (Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC), Vernal Kerato Conjunctivitis (VKC), Atopic Kerato Conjunctivitis (AKC) And Giant Papillary Conjunctivitis (GPC)), Drugs Profile (Zerviate, OTX-DP, ADX-102, PRT-2761, CVXL-0074, AK-002, Bertilimumab, Reproxalap, ST-266, SYL-116011) Companies (Ocular Therapeutix Inc., Portola Pharmaceuticals Inc., Alcon, Santen Pharmaceutical Co., Ltd., and Novartis)" provides a detailed analysis of Allergic Conjunctivitis Industry.

Country - Market, Patient Numbers and Treated Patient Numbers breakup from 9 viewpoints:

1. India

2. China

3. Japan

4. United States

5. United Kingdom

6. France

7. Germany

8. Italy

9. Spain

Disease - Market Breakup from 4 viewpoints:

1. Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC)

2. Vernal Kerato Conjunctivitis (VKC)

3. Atopic Kerato Conjunctivitis (AKC)

4. Giant Papillary Conjunctivitis (GPC)

Drugs - Market Breakup from 10 viewpoints:

1. Zerviate

2. OTX-DP

3. ADX-102

4. PRT-2761

5. CVXL-0074

6. AK-002

7. Bertilimumab

8. Reproxalap

9. ST-266

10. SYL-116011

Company Insights:

  • Overviews
  • Recent Developments
  • Revenues

Companies Covered:

1. Ocular Therapeutix Inc.

2. Portola Pharmaceuticals Inc.

3. Alcon

4. Santen Pharmaceutical Co., Ltd.

5. Novartis

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges

5. Global Allergic Conjunctivitis Market and Patients Analysis

  • 5.1 Market
  • 5.2 Patient Numbers
  • 5.3 Treated Patient Numbers

6. Share Analysis - Global Allergic Conjunctivitis

  • 6.1 Country Market Share
  • 6.2 Patients Population Share
  • 6.3 Treated Patients Population Share
  • 6.4 By Disease Type Share

7. India - Allergic Conjunctivitis Analysis

  • 7.1 Market
  • 7.2 Patient Numbers
  • 7.3 Treated Patient Numbers

8. China - Allergic Conjunctivitis Analysis

  • 8.1 Market
  • 8.2 Patient Numbers
  • 8.3 Treated Patient Numbers

9. Japan - Allergic Conjunctivitis Analysis

  • 9.1 Market
  • 9.2 Patient Numbers
  • 9.3 Treated Patient Numbers

10. United States - Allergic Conjunctivitis Analysis

  • 10.1 Market
  • 10.2 Patient Numbers
  • 10.3 Treated Patient Numbers

11. United Kingdom - Allergic Conjunctivitis Analysis

  • 11.1 Market
  • 11.2 Patient Numbers
  • 11.3 Treated Patient Numbers

12. France - Allergic Conjunctivitis Analysis

  • 12.1 Market
  • 12.2 Patient Numbers
  • 12.3 Treated Patient Numbers

13. Germany - Allergic Conjunctivitis Analysis

  • 13.1 Market
  • 13.2 Patient Numbers
  • 13.3 Treated Patient Numbers

14. Italy - Allergic Conjunctivitis Analysis

  • 14.1 Market
  • 14.2 Patient Numbers
  • 14.3 Treated Patient Numbers

15. Spain - Allergic Conjunctivitis Analysis

  • 15.1 Market
  • 15.2 Patient Numbers
  • 15.3 Treated Patient Numbers

16. Disease Type - Global Allergic Conjunctivitis Market

  • 16.1 Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC
  • 16.2 Vernal Keratoconjunctivitis (VKC)
  • 16.3 Atopic Keratoconjunctivitis (AKC)
  • 16.4 Giant Papillary Conjunctivitis (GPC)

17. Global Allergic Conjunctivitis Pipeline Drugs

  • 17.1 Zerviate
  • 17.2 OTX-DP (Dexamethasone Insert)
  • 17.3 ADX-102
  • 17.4 PRT2761
  • 17.5 CVXL-0074
  • 17.6 AK-002
  • 17.7 Bertilimumab
  • 17.8 Reproxalap
  • 17.9 ST-266
  • 17.10 SYL-116011

18. Porters Five Forces

  • 18.1 Overview
  • 18.2 Bargaining Power of Buyers
  • 18.3 Bargaining Power of Suppliers
  • 18.4 Degree of Competition
  • 18.5 Threat of New Entrants
  • 18.6 Threat of Substitutes

19. Company Analysis

  • 19.1 Ocular Therapeutix Inc.
    • 19.1.1 Overview
    • 19.1.2 Recent Development
    • 19.1.3 Revenue
  • 19.2 Portola Pharmaceuticals Inc.
    • 19.2.1 Overview
    • 19.2.2 Recent Development
    • 19.2.3 Revenue
  • 19.3 Alcon
    • 19.3.1 Overvie
    • 19.3.2 Recent Development
    • 19.3.3 Revenue
  • 19.4 Santen Pharmaceutical Co., Ltd.
    • 19.4.1 Overview
    • 19.4.2 Recent Development
    • 19.4.3 Revenue
  • 19.5 Novartis
    • 19.5.1 Overview
    • 19.5.2 Recent Developmen
    • 19.5.3 Revenue

List of Figures

  • Figure-01: Global - Allergic Conjunctivitis Market (Million US$), 2016 - 2021
  • Figure-02: Global - Forecast for Allergic Conjunctivitis Market (Million US$), 2022 - 2027
  • Figure-03: Global - Allergic Conjunctivitis Patient Numbers (Million), 2016 - 2021
  • Figure-04: Global - Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2022 - 2027
  • Figure-05: Global - Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 - 2021
  • Figure-06: Global - Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2022 - 2027
  • Figure-07: India - Allergic Conjunctivitis Market (Million US$), 2016 - 2021
  • Figure-08: India - Forecast for Allergic Conjunctivitis Market (Million US$), 2022 - 2027
  • Figure-09: India - Allergic Conjunctivitis Patient Numbers (Million), 2016 - 2021
  • Figure-10: India - Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2022 - 2027
  • Figure-11: India - Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 - 2021
  • Figure-12: India - Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2022 - 2027
  • Figure-13: China - Allergic Conjunctivitis Market (Million US$), 2016 - 2021
  • Figure-14: China - Forecast for Allergic Conjunctivitis Market (Million US$), 2022 - 2027
  • Figure-15: China - Allergic Conjunctivitis Patient Numbers (Million), 2016 - 2021
  • Figure-16: China - Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2022 - 2027
  • Figure-17: China - Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 - 2021
  • Figure-18: China - Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2022 - 2027
  • Figure-19: Japan - Allergic Conjunctivitis Market (Million US$), 2016 - 2021
  • Figure-20: Japan - Forecast for Allergic Conjunctivitis Market (Million US$), 2022 - 2027
  • Figure-21: Japan - Allergic Conjunctivitis Patient Numbers (Million), 2016 - 2021
  • Figure-22: Japan - Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2022 - 2027
  • Figure-23: Japan - Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 - 2021
  • Figure-24: Japan - Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2022 - 2027
  • Figure-25: United States - Allergic Conjunctivitis Market (Million US$), 2016 - 2021
  • Figure-26: United States - Forecast for Allergic Conjunctivitis Market (Million US$), 2022 - 2027
  • Figure-27: United States - Allergic Conjunctivitis Patient Numbers (Million), 2016 - 2021
  • Figure-28: United States - Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2022 - 2027
  • Figure-29: United States - Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 - 2021
  • Figure-30: United States - Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2022 - 2027
  • Figure-31: United Kingdom - Allergic Conjunctivitis Market (Million US$), 2016 - 2021
  • Figure-32: United Kingdom - Forecast for Allergic Conjunctivitis Market (Million US$), 2022 - 2027
  • Figure-33: United Kingdom - Allergic Conjunctivitis Patient Numbers (Million), 2016 - 2021
  • Figure-34: United Kingdom - Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2022 - 2027
  • Figure-35: United Kingdom - Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 - 2021
  • Figure-36: United Kingdom - Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2022 - 2027
  • Figure-37: France - Allergic Conjunctivitis Market (Million US$), 2016 - 2021
  • Figure-38: France - Forecast for Allergic Conjunctivitis Market (Million US$), 2022 - 2027
  • Figure-39: France - Allergic Conjunctivitis Patient Numbers (Million), 2016 - 2021
  • Figure-40: France - Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2022 - 2027
  • Figure-41: France - Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 - 2021
  • Figure-42: France - Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2022 - 2027
  • Figure-43: Germany - Allergic Conjunctivitis Market (Million US$), 2016 - 2021
  • Figure-44: Germany - Forecast for Allergic Conjunctivitis Market (Million US$), 2022 - 2027
  • Figure-45: Germany - Allergic Conjunctivitis Patient Numbers (Million), 2016 - 2021
  • Figure-46: Germany - Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2022 - 2027
  • Figure-47: Germany - Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 - 2021
  • Figure-48: Germany - Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2022 - 2027
  • Figure-49: Italy - Allergic Conjunctivitis Market (Million US$), 2016 - 2021
  • Figure-50: Italy - Forecast for Allergic Conjunctivitis Market (Million US$), 2022 - 2027
  • Figure-51: Italy - Allergic Conjunctivitis Patient Numbers (Million), 2016 - 2021
  • Figure-52: Italy - Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2022 - 2027
  • Figure-53: Italy - Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 - 2021
  • Figure-54: Italy - Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2022 - 2027
  • Figure-55: Spain - Allergic Conjunctivitis Market (Million US$), 2016 - 2021
  • Figure-56: Spain - Forecast for Allergic Conjunctivitis Market (Million US$), 2022 - 2027
  • Figure-57: Spain - Allergic Conjunctivitis Patient Numbers (Million), 2016 - 2021
  • Figure-58: Spain - Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2022 - 2027
  • Figure-59: Spain - Allergic Conjunctivitis Treated Patient Numbers (Million), 2016 - 2021
  • Figure-60: Spain - Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2022 - 2027
  • Figure-61: Disease Type - Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC) Market (Million US$), 2016 - 2021
  • Figure-62: Disease Type - Forecast for Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC) Market (Million US$), 2022 - 2027
  • Figure-63: Disease Type - Vernal Keratoconjunctivitis (VKC) Market (Million US$), 2016 - 2021
  • Figure-64: Disease Type - Forecast for Vernal Keratoconjunctivitis (VKC) Market (Million US$), 2022 - 2027
  • Figure-65: Disease Type - Atopic Keratoconjunctivitis (AKC) Market (Million US$), 2016 - 2021
  • Figure-66: Disease Type - Forecast for Atopic Keratoconjunctivitis (AKC) Market (Million US$), 2022 - 2027
  • Figure-67: Disease Type - Giant Papillary Conjunctivitis (GPC) Market (Million US$), 2016 - 2021
  • Figure-68: Disease Type - Forecast for Giant Papillary Conjunctivitis (GPC) Market (Million US$), 2022 - 2027
  • Figure-69: Ocular Therapeutix Inc. - Global Revenue (Million US$), 2016 - 2021
  • Figure-70: Ocular Therapeutix Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-71: Portola Pharmaceuticals Inc. - Global Revenue (Million US$), 2016 - 2021
  • Figure-72: Portola Pharmaceuticals Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-73: Alcon - Global Revenue (Million US$), 2016 - 2021
  • Figure-74: Alcon - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-75: Santen Pharmaceutical Co., Ltd. - Global Revenue (Million US$), 2016 - 2021
  • Figure-76: Santen Pharmaceutical Co., Ltd. - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-77: Novartis - Global Revenue (Million US$), 2016 - 2021
  • Figure-78: Novartis - Forecast for Global Revenue (Million US$), 2022 - 2027

List of Tables

  • Table-01: Global - Allergic Conjunctivitis Market Share by Countries (Percent), 2018 - 2021
  • Table-02: Global - Forecast for Allergic Conjunctivitis Market Share by Countries (Percent), 2022 - 2027
  • Table-03: Global - Allergic Conjunctivitis Patients Population Share by Countries (Percent), 2018 - 2021
  • Table-04: Global - Forecast for Allergic Conjunctivitis Patients Population Share by Countries (Percent), 2022 - 2027
  • Table-05: Global - Allergic Conjunctivitis Treated Patients Population Share by Countries (Percent), 2018 - 2021
  • Table-06: Global - Forecast for Allergic Conjunctivitis Treated Patients Population Share by Countries (Percent), 2022 - 2027
  • Table-07: Global - Allergic Conjunctivitis Market Share by Disease Type (Percent), 2018 - 2021
  • Table-08: Global - Forecast for Allergic Conjunctivitis Market Share by Disease Type (Percent), 2022 - 2027